



**RHYTHM**<sup>™</sup>  
BIOSCIENCES



# Business Update

18<sup>TH</sup> MARCH 2026

ersonal use only

# Disclaimer

This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

# Agenda

- Company Summary
- Recent ASX market updates
- Upcoming catalysts / inflection points?
- Q&A



# Detecting Cancer Earlier. Saving Lives.

Our purpose is clear: through innovative diagnostics, we are enabling the earliest possible detection of cancer.



## Product Strategy



EARLIEST STAGE

**geneType™**  
Genetic Risk Testing

Identifies individuals at elevated genetic risk – detecting the threat at the earliest possible stage, before symptoms or tumours develop.

**COLOSTAT®**

ACCESSIBLE DETECTION

**ColoSTAT®**  
Blood-Based Disease Detection

A simple blood test detecting colorectal cancer through circulating tumour markers – enabling non-invasive disease detection.

## Growth Opportunity and Drivers



**SIGNIFICANT MULTI-\$BN GLOBAL MARKET**

Targeting the rapidly growing global cancer risk assessment, cancer detection and screening market



**EXTENSIVE CLINICAL EVALUATION**

Building an evidence base for confident clinical adoption.



HARVARD  
UNIVERSITY



Memorial Sloan Kettering  
Cancer Center.



THE UNIVERSITY OF  
MELBOURNE



**CAPITAL EFFICIENT GROWTH**

A capital-efficient model that positions Rhythm for long-term commercial success as we move toward full commercialisation.

# Investment Highlights



Solving a significant and worsening global problem costing healthcare systems \$billions



Portfolio of valuable, patented and clinically validated assets



Turnaround phase nearing completion, business transformation underway




Business well placed for global commercial growth

## CORPORATE SNAPSHOT

17th March 2026

ASX Code	RHY
Share Price	\$0.21
Shares on Issue	329.5M
Unlisted & Listed Options	109M
Market Capitalisation	\$70.56M
Cash in Bank (31 December 2025)	\$1.397M
Top 20 Shareholders	42%



# Recent ColoSTAT® ASX Market Updates



1. Rhythm ISO15189 Accreditation & ColoSTAT® Commercialisation Initiation 12 December 2025
2. Manufacturing Agreement for ColoSTAT® Signed 3 February 2026
3. First Physician Enrolled in the ColoSTAT® Access Program (CAP) 11 February 2026
4. ColoSTAT® Services Agreement with 4Cyte Pathology 17 February 2026
5. Exercise of RHYO Options Underwritten for \$5.5m 25 February 2026
6. NHS Evaluation of ColoSTAT® Commences 26 February 2026
7. NATA Accreditation of ColoSTAT® Clinical Testing Service 9 March 2026
8. First ColoSTAT® Sale 11 March 2026

# ColoSTAT<sup>®</sup> Achieves NATA Accreditation



9<sup>th</sup> March 2026: The National Association of Testing Authorities (NATA) — Australia's independent peak laboratory accreditation body — has confirmed that ColoSTAT<sup>®</sup> satisfies all applicable technical and quality requirements under ISO 15189:2022

## ★ WHY THIS MATTERS

- NATA Accreditation confirms that ColoSTAT<sup>®</sup> meets the **quality and performance requirements** required by ISO15189:2022
- NATA accreditation is a prerequisite for **physician confidence** and broad clinical adoption of ColoSTAT<sup>®</sup>.
- NATA is the TGA designate and ColoSTAT<sup>®</sup> has completed the highest level of regulatory review available in Australia for a clinical service.

Regulatory Assessment Complete

## ◆ WHAT THIS ENABLES

- Physicians can order ColoSTAT<sup>®</sup> as an **accredited test**, satisfying clinical governance and institutional procurement.
- NATA accreditation is a formal prerequisite for a Medicare Benefits Schedule (MBS) reimbursement application — an essential step toward government-funded patient access.
- Strengthens ColoSTAT<sup>®</sup>'s credibility.

Ready for Growth

## ▶ WHAT'S NEXT

- Scaling of ColoSTAT<sup>®</sup> in Australia.
- Collection of qualified Real-world evidence to support application for MBS reimbursement to unlock government-funded access for all eligible Australian patients.
- Prepare for roll out in additional geographical markets.

Global Expansion

# ColoSTAT<sup>®</sup> Services Agreement with 4Cyte Pathology



17<sup>th</sup> Feb 2026: Rhythm signs a non-exclusive ColoSTAT<sup>®</sup> distribution agreement with 4Cyte Pathology, with access to more than 1,000 pathology collection centres across NSW, VIC and QLD.

## ★ WHY THIS MATTERS

- **Patient Access:** 4Cyte is a top-3 Australian pathology network — immediate access to thousands of potential patients.
- Access to **logistical infrastructure:** Clinical partnerships, collection centres and patient sample distribution network.
- **Commercial Validation:** Confirms clinical demand.

National Commercial Infrastructure

## ◆ WHAT THIS ENABLES

- ColoSTAT<sup>®</sup> will be orderable across the entire 4Cyte network, with patient samples routed to Rhythm's Parkville lab.
- Allows Rhythm to scale ColoSTAT<sup>®</sup> across the 4Cyte network.
- Drives test volume growth with minimal additional investment – capital efficient growth.

Ready for Growth

## ▶ WHAT'S NEXT

- Activation of 4Cyte collection centres and clinical partners. Plan to roll-out new sites each week.
- Physician education and awareness campaign within the 4Cyte network to drive initial test orders.
- Collection of real-world evidence from 4Cyte orders within the ColoSTAT<sup>®</sup> Access Program.

Growth Acceleration

# First ColoSTAT<sup>®</sup> Sale

11<sup>th</sup> March 2026: Rhythm completes the first commercial sale of its blood based ColoSTAT<sup>®</sup> colorectal cancer test, marking the commencement of the Company's commercial clinical diagnostic testing operations.

## ★ WHY THIS MATTERS

- Provides clinical and **commercial validation** through the actions of the prescribing physician and paying patient.
- Demonstrates the **logistical pathway** (sample collection → transport → Parkville lab → clinical report) is fully operational, de-risking commercial scale-up for investors.
- The NATA accreditation of the ColoSTAT<sup>®</sup> testing service underpins all subsequent commercial sales.

End-to-End Commercial Validation

## ◆ WHAT THIS ENABLES

- **Scaling:** This proven ColoSTAT<sup>®</sup> test ordering and fulfilment pathway can now be scaled.
- Rhythm can now report ColoSTAT<sup>®</sup> revenue from clinical test sales, a new revenue line alongside existing geneType<sup>™</sup> revenues.
- Real-world test data generation begins immediately.

Ready to Scale

## ▶ WHAT'S NEXT

- Accelerate ColoSTAT<sup>®</sup> Access Program physician enrolment and drive test volume growth through the 4Cyte networks.
- Accumulate clinical performance data from real-world tests to support MBS reimbursement application.
- Develop **additional pathology distribution partnerships** to expand the commercial footprint.

Growth Acceleration

# RHYO Options Underwritten: \$5.5m Cash Secured

25<sup>th</sup> Feb. 2026: RHY secures underwriting support for RHYO listed options expiring 31 March 2026, guaranteeing a minimum of \$5.5m in new capital at \$0.20 per share.



## ★ WHY THIS MATTERS

- Underwriting de-risks the outcome — RHY secures minimum \$5.5m regardless of individual option holder take-up.
- Funds arrive at a critical moment: ColoSTAT<sup>®</sup> is live commercially and geneType<sup>™</sup> is scaling internationally.

Growth Capital Access

## ◆ WHAT THIS ENABLES

- Extends the operational runway to support the commercial launch phase for both ColoSTAT<sup>®</sup> and geneType<sup>™</sup>.
- Fund commercial activities: marketing, promotion and distribution for both ColoSTAT<sup>®</sup> and geneType<sup>™</sup>.
- Fund ColoSTAT<sup>®</sup> clinical and economic studies.
- Restart lung cancer blood test development.

Drive Growth


## ▶ WHAT'S NEXT

- Option exercise window closes 31 March 2026 — final proceeds confirmed shortly after.
- Capital deployed to drive commercialisation: ColoSTAT<sup>®</sup> Access Program and geneType<sup>™</sup> geographic expansion.
- Strengthened balance sheet supports pursuit of further strategic product opportunities.

Strengthening the Pipeline

# Preparing for Growth

Leveraging our core business enablers to build a resilient high growth enterprise



## BUSINESS ENABLERS

Capital Efficient Growth

Clinical Evidence

Strategic Partnerships

Continuous Improvement

# Upcoming Value Inflection Points



Personal use only

PRODUCT	MILESTONE	DESCRIPTION	COMPLETION DATE
ColoSTAT®	<b>Scaling commercial footprint</b>	Activation of 4Cyte collection centres	Q4 FY2026
geneType™	<b>geneType™ strategic partnerships</b>	Establishment of key international and domestic commercial partners	Ongoing from Q3 FY2026
ColoSTAT®	<b>ColoSTAT® Access Program</b>	Complete enrolment for the ColoSTAT® Access Program	Q3 FY2026
ColoSTAT®	<b>ColoSTAT® MBS Strategy</b>	Complete strategy design for submission to MSAC	Q4 FY2026
geneType™	<b>geneType™ menu expansion</b>	Prototype of lung cancer geneType™ complete	Q4 FY2026
ColoSTAT®	<b>International expansion: UK</b>	Completion of first phase of NHS ColoSTAT® evaluation	Q4 FY2026
ColoSTAT®	<b>International Expansion</b>	Establish ColoSTAT® commercialisation partner beyond Australia and UK	Q1 FY2027

# Board and Management Team

Highly experienced team focussed on execution



**David Atkins, PhD**  
CEO & MD

Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Experience in product development and commercial leadership in the global medical device and diagnostic industry. Also, an active member of BioNSW and InGeNA.



**Sue MacLeman**  
Non-Executive Director

30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck and SME's.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently Chair of Medicines Australia, NED & Chair at Viral Vector Manufacturing Facility, Smartways Logistics, Healthcare Translation Group, & OMICO & member of the National Research Infrastructure (NRI) Advisory Group.



**Gavin Fox-Smith**  
Non-Executive Chairman

38 years as a leader and champion of Medical Technology in Australia/NZ and Asia.

Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation.

Gavin was previously CEO of Omnigon, a private Australian company in the Ostomy Care market.



**Jackson Jones**  
Chief Commercial Officer



**Nir Dvorski**  
Chief Operations Officer



**Erika Spaeth, PhD**  
Director of Genetype Clinical & Scientific Affairs



**Andy Feber, PhD**  
Director of Diagnostic Clinical & Scientific Affairs



**Gary Goh**  
Head of Laboratory Operations and RA/QA



**Andrea Steele**  
General Counsel

ersonal use only



**Thank you!**

[david.atkins@rhythmbio.com](mailto:david.atkins@rhythmbio.com)

[www.rhythmbio.com](http://www.rhythmbio.com)